Phase IIa Clinical Biomarker Trial of Dietary Arginine Restriction and Aspirin in Colorectal Cancer Patients

SIMPLE SUMMARY: The authors present a phase IIa clinical biomarker trial of colorectal cancer (CRC) survivors treated with a polyamine-inhibitory regimen (dietary arginine restriction plus daily aspirin 325 mg) as a potential future strategy for tertiary prevention of CRC (i.e., preventing colorecta...

Descripción completa

Detalles Bibliográficos
Autores principales: Zell, Jason A., Taylor, Thomas H., Albers, C. Gregory, Carmichael, Joseph C., McLaren, Christine E., Wenzel, Lari, Stamos, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093153/
https://www.ncbi.nlm.nih.gov/pubmed/37046763
http://dx.doi.org/10.3390/cancers15072103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093153/
https://www.ncbi.nlm.nih.gov/pubmed/37046763
http://dx.doi.org/10.3390/cancers15072103

Ejemplares similares